| Year |
Citation |
Score |
| 2021 |
Patil NS, Zou W, Mocci S, Sandler A, Ballinger M, Flynn S, Kowanetz M, Hegde PS. C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients. Plos One. 16: e0246486. PMID 33534859 DOI: 10.1371/journal.pone.0246486 |
0.45 |
|
| 2020 |
Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. The New England Journal of Medicine. 383: 1328-1339. PMID 32997907 DOI: 10.1056/NEJMoa1917346 |
0.407 |
|
| 2020 |
Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treatment Reviews. 86: 102017. PMID 32335505 DOI: 10.1016/j.ctrv.2020.102017 |
0.313 |
|
| 2020 |
Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, Soo R, Conter HJ, Kozuki T, Huang KC, Graupner V, Sun SW, Hoang T, Jessop H, McCleland M, ... ... Sandler A, et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32302702 DOI: 10.1016/J.Jtho.2020.03.028 |
0.583 |
|
| 2019 |
Peters S, Kim AW, Solomon B, Gandara DR, Dziadziuszko R, Brunelli A, Garassino MC, Reck M, Wang L, To I, Sun SW, Gitlitz BJ, Sandler A, Rizvi N. IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: ii30. PMID 32131215 DOI: 10.1093/Annonc/Mdz064.014 |
0.515 |
|
| 2019 |
Reck M, Shankar G, Lee A, Coleman S, McCleland M, Papadimitrakopoulou VA, Socinski MA, Sandler A. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with mutations. Expert Review of Respiratory Medicine. 1-12. PMID 31829747 DOI: 10.1080/17476348.2020.1701439 |
0.512 |
|
| 2019 |
West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology. PMID 31122901 DOI: 10.1016/S1470-2045(19)30167-6 |
0.562 |
|
| 2019 |
Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel JD, von Pawel J, O'Hear C, Lai C, Hu S, Ballinger M, Sandler A, et al. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer (Amsterdam, Netherlands). 128: 105-112. PMID 30642441 DOI: 10.1016/J.Lungcan.2018.12.017 |
0.492 |
|
| 2019 |
Socinski MA, Jotte RM, Cappuzzo F, Mok TSK, West H, Nishio M, Papadimitrakopoulou V, Orlandi FJ, Stroyakovskiy D, Thomas CA, Nogami N, Barlesi F, Lee A, Shankar G, Yu W, ... ... Sandler A, et al. IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets). Journal of Clinical Oncology. 37: 9012-9012. DOI: 10.1200/Jco.2019.37.15_Suppl.9012 |
0.411 |
|
| 2019 |
Lin SH, Lin Y, Mok I, Young JA, Phan S, Sandler A, Papadimitrakopoulou V, Heymach J, Tsao AS. Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer. Journal of Clinical Oncology. 37: 8512-8512. DOI: 10.1200/Jco.2019.37.15_Suppl.8512 |
0.497 |
|
| 2019 |
Wong DJ, Fayette J, Guo Y, Kowgier M, Cohen E, Nin RM, Dechaphunkul A, Prabhash K, Geiger J, Bishnoi S, Schafer H, Matheny C, Kabbinavar F, Sandler A, Raben D, et al. Abstract CT123: IMvoke010: Randomized Phase III study of atezolizumab as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ct123 |
0.46 |
|
| 2019 |
West HL, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp H, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Archer V, Lohmann TO, ... ... Sandler A, et al. Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct200 |
0.544 |
|
| 2019 |
Mansfield AS, Liu SV, Szczęsna A, Havel L, Kzrakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok TS, Lam S, Shames DS, Liu J, ... ... Sandler A, et al. Abstract CT199: IMpower133: Primary efficacy and safety + CNS-related adverse events in a Ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct199 |
0.489 |
|
| 2019 |
Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Abreu DR, Hussein M, Soo R, Conter H, Kozuki T, Huang K, Graupner V, Sun S, Hoang T, Jessop H, Mccleland M, ... ... Sandler A, et al. OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC Journal of Thoracic Oncology. 14: S243-S244. DOI: 10.1016/J.Jtho.2019.08.484 |
0.367 |
|
| 2019 |
Rashdan S, Dahlberg S, Gerber D, Sandler A, Schiller J, Johnson D, Ramalingam S. OA07.05 High-Grade Chemotherapy-Induced Peripheral Neuropathy (CIPN): An Analysis of ECOG-ACRIN Lung Cancer Clinical Trials Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.444 |
0.454 |
|
| 2018 |
Mok TSK, Reck M, Horn L, Lam S, Shames DS, Liu J, Kabbinavar F, Lin W, Sandler A, Liu SV. IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: ix173. PMID 32177930 DOI: 10.1093/Annonc/Mdy483 |
0.429 |
|
| 2018 |
Cappuzzo F, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Archer V, Ochi Lohmann T, ... ... Sandler A, et al. IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii742-viii743. PMID 32138034 DOI: 10.1093/Annonc/Mdy424.065 |
0.508 |
|
| 2018 |
Haddad R, Wong DJ, Guo Y, Fayette J, Cohen EEW, Kowgier M, Sandler A, Matheny C, Kabbinavar F, Raben D. IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii397. PMID 32136984 DOI: 10.1093/Annonc/Mdy287.074 |
0.327 |
|
| 2018 |
von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, Hida T, Moro-Sibilot D, Conkling P, Gandara DR, Rittmeyer A, Gandhi M, Yu W, Matheny C, Patel H, ... Sandler A, et al. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. European Journal of Cancer (Oxford, England : 1990). 107: 124-132. PMID 30562710 DOI: 10.1016/J.Ejca.2018.11.020 |
0.551 |
|
| 2018 |
Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE, Wistuba I, Chaft J, Rizvi NA, Spigel DR, Spira A, Hirsch FR, Cohen V, Smith D, ... ... Sandler A, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proceedings of the National Academy of Sciences of the United States of America. PMID 30297397 DOI: 10.1073/Pnas.1802166115 |
0.529 |
|
| 2018 |
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, ... ... Sandler A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. The New England Journal of Medicine. PMID 30280641 DOI: 10.1056/Nejmoa1809064 |
0.49 |
|
| 2018 |
Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Aix SP, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, ... ... Sandler A, et al. Atezolizumab Treatment Beyond Progression in Advanced Non-Small Cell Lung Cancer: Results From the Randomized, Phase III OAK Study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30217492 DOI: 10.1016/J.Jtho.2018.08.2027 |
0.567 |
|
| 2018 |
Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, Lieber DS, Lipson D, Silterra J, Amler L, Riehl T, ... ... Sandler A, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nature Medicine. PMID 30082870 DOI: 10.1038/S41591-018-0134-3 |
0.514 |
|
| 2018 |
Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, ... ... Sandler A, et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal of Cancer (Oxford, England : 1990). 101: 201-209. PMID 30077125 DOI: 10.1016/J.Ejca.2018.06.031 |
0.493 |
|
| 2018 |
Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, Sandler A, Yu W, He P, Matheny C, Felizzi F, Rittmeyer A. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer. Clinical Lung Cancer. PMID 30017645 DOI: 10.1016/J.Cllc.2018.05.011 |
0.564 |
|
| 2018 |
Lee A, Sun S, Sandler A, Hoang T. Recent progress in therapeutic antibodies for cancer immunotherapy. Current Opinion in Chemical Biology. 44: 56-65. PMID 29885949 DOI: 10.1016/J.Cbpa.2018.05.006 |
0.399 |
|
| 2018 |
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, ... ... Sandler A, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. The New England Journal of Medicine. PMID 29863955 DOI: 10.1056/Nejmoa1716948 |
0.469 |
|
| 2018 |
Bonomi P, Blumenthal G, Ferris AS, Stewart DJ, Selig WKD, Krug LM, Allen J, Ison G, Langer CJ, Melemed A, Odogwu L, Basu Roy U, Sandler A. Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 13: 748-751. PMID 29793646 DOI: 10.1016/J.Jtho.2018.02.013 |
0.415 |
|
| 2018 |
Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis DL, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, ... ... Sandler A, et al. Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29777823 DOI: 10.1016/J.Jtho.2018.04.039 |
0.525 |
|
| 2018 |
Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ, Leon L, Fredrickson J, Kowanetz M, Sandler A, Funke R, Rizvi NA. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29775807 DOI: 10.1016/J.Jtho.2018.05.004 |
0.539 |
|
| 2018 |
Claret L, Jin JY, Ferté C, Winter H, Girish S, Stroh M, He P, Ballinger M, Sandler A, Joshi A, Rittmeyer A, Gandara DR, Soria JC, Bruno R. A model of overall survival predicts treatment outcomes with atezolizumab vs chemotherapy in non-small cell lung cancer based on early tumor kinetics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29685883 DOI: 10.1158/1078-0432.Ccr-17-3662 |
0.484 |
|
| 2018 |
Jotte RM, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodriguez Abreu D, Hussein MA, Soo RA, Conter HJ, Kozuki T, Silva C, Graupner V, Sun S, Lin RS, Kelsch C, Kowanetz M, ... ... Sandler A, et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. Journal of Clinical Oncology. 36: LBA9000-LBA9000. DOI: 10.1200/Jco.2018.36.18_Suppl.Lba9000 |
0.46 |
|
| 2018 |
Reck M, Karagiannis T, Wehler T, Shtivelband M, Gonzalez-Larriba J, Rothenstein J, Frueh M, Deng Y, Lopez-Chavez A, Sandler A, Socinski MA. Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC). Journal of Clinical Oncology. 36: 9047-9047. DOI: 10.1200/Jco.2018.36.15_Suppl.9047 |
0.473 |
|
| 2018 |
Socinski MA, Jotte RM, Cappuzzo F, Orlandi FJ, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley GG, Kelsch C, Lee A, Coleman S, Shen Y, ... ... Sandler A, et al. Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. Journal of Clinical Oncology. 36: 9002-9002. DOI: 10.1200/Jco.2018.36.15_Suppl.9002 |
0.468 |
|
| 2018 |
Lieber DS, White E, Silterra J, Zhong S, Brennan T, Coyne M, Kennedy M, Gandara DR, Kowanetz M, Paul SM, Schleifman E, Li Y, Rittmeyer A, Fehrenbacher L, Amler L, ... ... Sandler A, et al. Abstract A41: Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A41 |
0.458 |
|
| 2018 |
Kowanetz M, Socinski MA, Zou W, McCleland M, Yang N, Chavez AL, Spira A, Mazières J, Braiteh F, Shames D, Sandler A, Reck M. Abstract CT076: IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct076 |
0.498 |
|
| 2018 |
Patil N, Zou W, Mocci S, Gupta V, Molinero L, Sandler A, Ballinger M, Flynn S, Kowanetz M, Hegde P. Abstract 5707: On-treatment changes in CRP as a surrogate for overall survival for atezolizumab benefit in 2ndline NSCLC Immunology. DOI: 10.1158/1538-7445.Am2018-5707 |
0.373 |
|
| 2018 |
Rittmeyer A, Gadgeel S, Kowanetz M, Zou W, Hirsch F, Kerr K, Gandara D, Barlesi F, Park K, McCleland M, Koeppen H, Ballinger M, Sandler A, Hegde P. Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study Pneumologie. 72: S50-S51. DOI: 10.1055/S-0037-1619252 |
0.425 |
|
| 2018 |
Rittmeyer A, Gandara D, Kowanetz M, Mok T, Fehrenbacher L, Fabrizio D, Otto G, Malboeuf C, Lieber D, Paul S, Amler L, Riehl T, Schleifman E, Cummings C, Hegde P, ... ... Sandler A, et al. Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK) Pneumologie. 72: S49-S50. DOI: 10.1055/S-0037-1619250 |
0.395 |
|
| 2018 |
Pietras R, Xu H, Hu X, Matheny C, Sandler A, Patel M. P1.04-33 Retrospective Descriptive Analysis of Metformin with Atezolizumab in Advanced Non-Small Cell Lung Cancer in The OAK Trial Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.748 |
0.473 |
|
| 2018 |
Papadimitrakopoulou V, Cobo M, Bordoni R, Dubray-Longeras P, Szalai Z, Ursol G, Novello S, Orlandi F, Ball S, Goldschmidt J, Sanborn R, Hoang T, Mendus D, Deng Y, Kowanetz M, ... ... Sandler A, et al. OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.262 |
0.471 |
|
| 2018 |
Lin S, Lin X, Clay D, Yao L, Mok I, Gomez D, Kurie J, Simon G, Blumenschein G, Young J, Phan S, Sandler A, Papadimitrakopoulou V, Heymach J, Tsao A. OA01.06 DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.237 |
0.509 |
|
| 2018 |
Rizvi N, Gandara D, Solomon B, Kim A, Brunelli A, Sun S, Gitlitz B, Tajima K, Lin W, Sandler A, Peters S. P2.17-27 IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab + Chemotherapy Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.1553 |
0.431 |
|
| 2018 |
Liu S, Mansfield A, Szczesna A, Havel L, Krzakowski M, Hochmair M, Huemer F, Losonczy G, Johnson M, Nishio M, Reck M, Mok T, Lam S, Shames D, Liu J, ... ... Sandler A, et al. PL02.07 IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.013 |
0.376 |
|
| 2017 |
Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, ... ... Sandler A, et al. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016719476. PMID 28609226 DOI: 10.1200/Jco.2016.71.9476 |
0.541 |
|
| 2017 |
Vansteenkiste J, Wauters E, Park K, Rittmeyer A, Sandler A, Spira A. Prospects and progress of atezolizumab in non-small cell lung cancer. Expert Opinion On Biological Therapy. PMID 28335643 DOI: 10.1080/14712598.2017.1309389 |
0.558 |
|
| 2017 |
West HJ, Nishio M, Dols MC, Saito H, Howland M, Hoang T, Asakawa T, Sandler A, Socinski MA. IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps9101 |
0.544 |
|
| 2017 |
Horn L, Mansfield AS, Reck M, Mok T, Spira AI, Tang X, Lam S, Kabbinavar FF, Lopez-Chavez A, Sandler A, Liu SV. Phase I/III trial of atezolizumab with carboplatin and etoposide in ES-SCLC in first-line setting (IMpower133). Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps8584 |
0.509 |
|
| 2017 |
Wakelee HA, Altorki NK, Vallieres E, Zhou C, Zuo Y, Howland M, Xia F, Sandler A, Felip E. A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps8576 |
0.496 |
|
| 2017 |
Gandara DR, Von Pawel J, Sullivan RN, Helland A, Han J, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt JH, Gandhi M, Yun C, Yu W, Matheny C, ... ... Sandler A, et al. Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study. Journal of Clinical Oncology. 35: 9001-9001. DOI: 10.1200/Jco.2017.35.15_Suppl.9001 |
0.441 |
|
| 2017 |
Lin SH, Lin Y, Price J, Parker M, Gomez DR, Welsh JW, Komaki R, Kurie JM, Simon GR, Blumenschein GR, Young JA, Phan S, Sandler A, Papadimitrakopoulou V, Heymach J, et al. DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab). Journal of Clinical Oncology. 35: 3064-3064. DOI: 10.1200/Jco.2017.35.15_Suppl.3064 |
0.507 |
|
| 2017 |
Rittmeyer A, Smith D, Vansteenkiste J, Fehrenbacher L, Park K, Mazieres J, Artal-Cortes A, Lewanski C, Braiteh F, Yi J, He P, Zou W, Waterkamp D, Ballinger M, Chen D, ... Sandler A, et al. Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR) Pneumologie. 71: S1-S125. DOI: 10.1200/Jco.2016.34.15_Suppl.9028 |
0.567 |
|
| 2017 |
Reck M, Socinski MA, Cappuzzo F, Orlandi F, Stroyakovskii D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Shen Y, ... ... Sandler A, et al. LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx760.002 |
0.497 |
|
| 2017 |
Gadgeel S, Kowanetz M, Zou W, Hirsch F, Kerr K, Gandara D, Barlesi F, Park K, McCleland M, Koeppen H, Ballinger M, Sandler A, Hegde P, Rittmeyer A. Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study Annals of Oncology. 28: v460-v461. DOI: 10.1093/Annonc/Mdx380.001 |
0.425 |
|
| 2017 |
Gandara D, Kowanetz M, Mok T, Rittmeyer A, Fehrenbacher L, Fabrizio D, Otto G, Malboeuf C, Lieber D, Paul S, Amler L, Riehl T, Schleifman E, Cummings C, Hegde P, ... ... Sandler A, et al. Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK) Annals of Oncology. 28: v460. DOI: 10.1093/Annonc/Mdx380 |
0.395 |
|
| 2017 |
Jassem J, Marinis Fd, Spigel DR, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Herbst RS. 143TiPIMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx091.063 |
0.508 |
|
| 2017 |
Reck M, Mansfield AS, Liu SV, Mok TSK, Tang X, Lam S, Kabbinavar F, Lopez-Chavez A, Sandler A, Horn L. 58TiPIMpower133: Phase I/III trial of first-line atezolizumab with carboplatin and etoposide in ES-SCLC Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx088.008 |
0.391 |
|
| 2017 |
Schütte W, Barlesi F, Park K, Ciardiello F, Pawel J, Gadgeel S, Hida T, Kowalski D, Cobo Dols M, Cortinovis D, Leach J, Polikoff J, Gandara D, Barrios C, Chen D, ... ... Sandler A, et al. Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC Pneumologie. 71: S1-S125. DOI: 10.1055/S-0037-1598278 |
0.57 |
|
| 2017 |
Eberhardt W, Garassino M, Rizvi N, Besse B, Jänne P, Peters S, Toh CK, Kurata T, Costa EC, Koczywas M, Font EF, Chaft J, Qiu J, Kowanetz M, Zou W, ... ... Sandler A, et al. Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study Pneumologie. 71. DOI: 10.1055/S-0037-1598277 |
0.463 |
|
| 2017 |
Felip E, Wakelee H, Vallieres E, Zhou C, Zuo Y, Xia F, Sandler A, Altorki N. P2.04-004 IMpower010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.11.017 |
0.418 |
|
| 2017 |
Bordoni R, Ciardiello F, Von Pawel J, Cortinovis D, He P, Karagiannis T, Ballinger M, Sandler A, Yu W, Felizzi F, Rittmeyer A. P1.01-052 Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-Small-Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 12: S1914-S1915. DOI: 10.1016/J.Jtho.2017.09.706 |
0.502 |
|
| 2017 |
Park K, Lewanski C, Gadgeel S, Fehrenbacher L, Mazieres J, Rittmeyer A, Han J, Artal-Cortes A, Braiteh F, Gandhi M, Yu W, Matheny C, He P, Sandler A, Ballinger M, et al. MA 10.03 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR) Journal of Thoracic Oncology. 12: S1840. DOI: 10.1016/J.Jtho.2017.09.535 |
0.459 |
|
| 2017 |
Kowanetz M, Zou W, Mccleland M, Gandara D, Gadgeel S, Rittmeyer A, Barlesi F, Park K, Shames D, Koeppen H, Ballinger M, Sandler A, Hegde P. MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC Journal of Thoracic Oncology. 12: S1817-S1818. DOI: 10.1016/J.Jtho.2017.09.485 |
0.313 |
|
| 2017 |
Satouchi M, Fehrenbacher L, Dols MC, Han J, Von Pawel J, Bordoni R, Hida T, Park K, Moro-Sibilot D, Conkling P, Matheny C, Yu W, He P, Kowanetz M, Gandhi M, ... ... Sandler A, et al. OA 17.07 Long-Term Survival in Atezolizumab-Treated Patients with 2L+ NSCLC from Ph III Randomized OAK Study Journal of Thoracic Oncology. 12: S1794. DOI: 10.1016/J.Jtho.2017.09.432 |
0.412 |
|
| 2017 |
Carcereny E, Felip E, Reck M, Patel J, Heist R, Balmanoukian A, Chow L, Paz-Ares L, Qiu J, Coleman S, Mocci S, Sandler A, Kurata T, Shepherd F. OA 17.02 Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC Journal of Thoracic Oncology. 12: S1791-S1792. DOI: 10.1016/J.Jtho.2017.09.428 |
0.44 |
|
| 2017 |
Kowanetz M, Zou W, Shames D, Cummings C, Rizvi N, Spira A, Frampton G, Leveque V, Flynn S, Mocci S, Shankar G, Funke R, Ballinger M, Waterkamp D, Chen D, ... Sandler A, et al. OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients Journal of Thoracic Oncology. 12: S321-S322. DOI: 10.1016/J.Jtho.2016.11.343 |
0.525 |
|
| 2017 |
Garassino M, Rizvi N, Besse B, Jänne P, Christoph D, Peters S, Toh CK, Kurata T, Costa EC, Koczywas M, Felip E, Chaft J, Qiu J, Kowanetz M, Coleman S, ... ... Sandler A, et al. OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.239 |
0.469 |
|
| 2017 |
Gadgeel S, Ciardiello F, Rittmeyer A, Barlesi F, Cortinovis D, Barrios C, Hida T, Park K, Kowalski D, Cobo Dols M, Leach J, Polikoff J, Matheny C, He P, Kowanetz M, ... ... Sandler A, et al. PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses Journal of Thoracic Oncology. 12: S9-S10. DOI: 10.1016/J.Jtho.2016.11.011 |
0.528 |
|
| 2016 |
Gomez SL, Yang J, Lin SW, McCusker M, Sandler A, Patel M, Cheng I, Wakelee HA, Clarke CA. Lung Cancer Survival Among Chinese Americans, 2000 to 2010. Journal of Global Oncology. 2: 30-38. PMID 28717680 DOI: 10.1200/Jgo.2015.000539 |
0.32 |
|
| 2016 |
Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, ... ... Sandler A, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (London, England). PMID 27979383 DOI: 10.1016/S0140-6736(16)32517-X |
0.595 |
|
| 2016 |
Gordon MS, Herbst RS, Horn L, Soria JC, Gandhi L, Felip E, Sequist L, Spigel DR, Antonia SJ, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, ... Sandler A, et al. PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S309-S310. PMID 27969529 DOI: 10.1016/J.Jtho.2016.09.097 |
0.369 |
|
| 2016 |
Horn L, Reck M, Mok T, Johnson ML, Tang X, Lam S, Waterkamp D, Lopez-Chavez A, Sandler A, Giacconne G, Liu SV. PS01.57: IMpower133: a Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S305-S306. PMID 27969524 DOI: 10.1016/J.Jtho.2016.09.092 |
0.415 |
|
| 2016 |
Herbst RS, De Marinis F, Jassem J, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Spigel DR. PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1-Selected Chemotherapy-Naive NSCLC Patients: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S304-S305. PMID 27969523 DOI: 10.1016/J.Jtho.2016.09.091 |
0.509 |
|
| 2016 |
Vallieres E, Felip E, Altorki N, Zhou C, Zuo Y, Howland M, Xia F, Hoang T, Sandler A, Wakelee H. PS01.55: IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S304. PMID 27969522 DOI: 10.1016/J.Jtho.2016.09.090 |
0.46 |
|
| 2016 |
Jotte RM, Socinski MA, Reck M, Papadimitrakopoulou V, West HJ, Mok T, Sandler A, Mocci S, Coleman S, Asakawa T, Cappuzzo F. PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S302-S303. PMID 27969520 DOI: 10.1016/J.Jtho.2016.09.088 |
0.456 |
|
| 2016 |
Wakelee H, Patel JD, Heist R, Balmanoukian A, Besse B, Felip E, Carcereny Costa E, Chow LQ, Koczywas M, Garassino MC, Christoph D, Toh CK, Johnson ML, Chaft J, Kurata T, ... ... Sandler A, et al. ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S251-S252. PMID 27969443 DOI: 10.1016/J.Jtho.2016.09.009 |
0.498 |
|
| 2016 |
Han K, Claret L, Sandler A, Das A, Jin J, Bruno R. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation. Bmc Cancer. 16: 473. PMID 27412292 DOI: 10.1186/S12885-016-2455-2 |
0.39 |
|
| 2016 |
Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, ... ... Sandler A, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (London, England). PMID 26970723 DOI: 10.1016/S0140-6736(16)00587-0 |
0.63 |
|
| 2016 |
Papadimitrakopoulou V, Cappuzzo F, Jotte RM, Reck M, Mok T, Sandler A, Waterkamp D, Coleman S, Sugitani Y, Socinski MA. Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps9103 |
0.523 |
|
| 2016 |
Mazieres J, Fehrenbacher L, Rittmeyer A, Spira AI, Park K, Smith DA, Artal-Cortes A, Lewanski CR, Braiteh FS, Yi J, He P, Kowanetz M, Waterkamp D, Ballinger M, Chen DS, ... Sandler A, et al. Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR. Journal of Clinical Oncology. 34: 9032-9032. DOI: 10.1200/Jco.2016.34.15_Suppl.9032 |
0.529 |
|
| 2016 |
Smith DA, Vansteenkiste JF, Fehrenbacher L, Park K, Mazieres J, Rittmeyer A, Artal-Cortes A, Lewanski CR, Braiteh FS, Yi J, He P, Zou W, Kowanetz M, Waterkamp D, Ballinger M, ... ... Sandler A, et al. Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR). Journal of Clinical Oncology. 34: 9028-9028. DOI: 10.1200/JCO.2016.34.15_SUPPL.9028 |
0.506 |
|
| 2016 |
Schmid P, Hegde PS, Zou W, Kowanetz M, Mariathasan S, Molinero L, Gadgeel SM, Powles T, Van Der Heijden MS, Fasso M, O'Hear C, Ballinger M, Fine GD, Sandler A, Chen DS, et al. Association of PD-L2 expression in human tumors with atezolizumab activity. Journal of Clinical Oncology. 34: 11506-11506. DOI: 10.1200/Jco.2016.34.15_Suppl.11506 |
0.476 |
|
| 2016 |
Kowanetz M, Koeppen H, Zou W, Mariathasan S, Hellmann M, Kockx M, Chappey C, Kadel E, Smith D, Miley N, Leveque V, Funke R, Sandler A, McCaffery I, Amler L, et al. Abstract A017: PD-L1 as a predictive biomarker for atezolizumab (MPDL3280A; anti-PDL1) in non-small cell lung cancer (NSCLC) Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-A017 |
0.528 |
|
| 2016 |
Mok TSK, Horn L, Reck M, Johnson ML, Tang X, Lam S, Shames DS, Waterkamp D, Lopez-Chavez A, Sandler A, Giaccone G, Liu SV. 521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC) Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw598.002 |
0.455 |
|
| 2016 |
Mok TSK, Jotte RM, Cappuzzo F, Reck M, Papadimitrakopoulou V, West HJ, Sandler A, Mocci S, Coleman S, Asakawa T, Socinski MA. 483TiP A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw594.047 |
0.441 |
|
| 2016 |
Marinis FD, Jassem J, Spigel DR, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Herbst RS. 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts) Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw594.044 |
0.512 |
|
| 2016 |
Zhou C, Altorki N, Valliéres E, Felip E, Zuo Y, Howland M, Xia F, Hoang T, Sandler A, Wakelee H. 429TiP IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw592.004 |
0.466 |
|
| 2016 |
Barlesi F, Park K, Ciardiello F, von Pawel J, Gadgeel S, Hida T, Kowalski D, Dols M, Cortinovis D, Leach J, Polikoff J, Gandara D, Barrios C, Chen D, He P, ... ... Sandler A, et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC Annals of Oncology. 27: vi581. DOI: 10.1093/Annonc/Mdw435.43 |
0.547 |
|
| 2016 |
Horn L, Reck M, Mok TSK, Johnson M, Waterkamp D, Lam S, Tang X, Sandler A, Lopez-Chavez A, Giaccone G, Liu SV. A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133) Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw389.09 |
0.507 |
|
| 2016 |
Reck M, Papadimitrakopoulou VA, Cappuzzo F, Jotte R, Mok TSK, Sandler A, Waterkamp D, Coleman S, Asakawa T, Socinski M. Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw383.94 |
0.5 |
|
| 2016 |
Kowanetz M, Zou W, Shames D, Cummings C, Rizvi N, Spira A, Frampton G, Leveque V, Flynn S, Mocci S, Shankar G, Funke R, Ballinger M, Waterkamp D, Sandler A, et al. Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC Annals of Oncology. 27: vi23. DOI: 10.1093/Annonc/Mdw363.25 |
0.375 |
|
| 2016 |
Wakelee H, Altorki N, Vallieres E, Zhou C, Zuo Y, Howland M, Xia F, Hoang T, Sandler A, Felip E. P3.02c-050 IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: IT Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1845 |
0.461 |
|
| 2016 |
Marinis FD, Jassem J, Spigel D, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giacconne G, Herbst R. P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients: Topic: IT Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1837 |
0.527 |
|
| 2016 |
Liu S, Reck M, Mok T, Johnson M, Tang X, Lam S, Waterkamp D, Lopez-Chavez A, Sandler A, Giacconne G, Horn L. P3.02c-041 IMpower133: A Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1836 |
0.418 |
|
| 2016 |
Cappuzzo F, Reck M, Papadimitrakopoulou V, Jotte R, West H, Mok T, Sandler A, Mocci S, Coleman S, Asakawa T, Socinski M. P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: IT Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1833 |
0.46 |
|
| 2015 |
DeBusk K, Johnson N, Evans C, Sandler A, Ramalingam SS, Campbell A. Development Of A Patient-Reported Outcome (Pro) Assessment Of Core Non-Small Cell Lung Cancer (Nsclc) Symptoms. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: A471. PMID 26532645 DOI: 10.1016/j.jval.2015.09.1250 |
0.316 |
|
| 2015 |
Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, et al. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2667-74. PMID 26169611 DOI: 10.1200/Jco.2014.60.7317 |
0.537 |
|
| 2015 |
Gomez SL, Yang J, Lin SW, McCusker M, Sandler A, Cheng I, Wakelee HA, Patel M, Clarke CA. Incidence Trends of Lung Cancer by Immigration Status among Chinese Americans. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 25990553 DOI: 10.1158/1055-9965.Epi-15-0123 |
0.374 |
|
| 2015 |
Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, ... Sandler A, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1000-7. PMID 25667274 DOI: 10.1200/Jco.2014.58.2007 |
0.455 |
|
| 2015 |
Langer CJ, Socinski MA, Patel JD, Sandler AB, Schiller JH, Leon L, Hazard SJ, Ramalingam SS. Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. American Journal of Clinical Oncology. PMID 25628268 DOI: 10.1097/Coc.0000000000000163 |
0.438 |
|
| 2015 |
Grilley-Olson JE, Keedy VL, Sandler A, Moore DT, Socinski MA, Stinchcombe TE. A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. The Oncologist. 20: 105-6. PMID 25616430 DOI: 10.1634/Theoncologist.2014-0327 |
0.462 |
|
| 2015 |
Taylor MH, Sandler A, Urba WJ, Omuro AMP, Gorman GS, Karmali RA. Effect of Carboxyamidotriazole Orotate, a Modulator of Calcium-Dependent Signaling Pathways, on Advanced Solid Tumors Journal of Cancer Therapy. 6: 322-333. DOI: 10.4236/Jct.2015.64035 |
0.382 |
|
| 2015 |
Horn L, Spigel DR, Gettinger SN, Antonia SJ, Gordon MS, Herbst RS, Sequist LV, Chappey C, Kowanetz M, Sandler A, Soria J. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. Journal of Clinical Oncology. 33: 8029-8029. DOI: 10.1200/Jco.2015.33.15_Suppl.8029 |
0.501 |
|
| 2015 |
Spigel DR, Chaft JE, Gettinger SN, Chao BH, Dirix LY, Schmid P, Chow LQM, Chappey C, Kowanetz M, Sandler A, Funke RP, Rizvi NA. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: 8028-8028. DOI: 10.1200/Jco.2015.33.15_Suppl.8028 |
0.533 |
|
| 2015 |
Gettinger SN, Kowanetz M, Koeppen H, Wistuba II, Kockx M, Kadel EE, Rizvi NA, Spira AI, Hirsch FR, Boyd Z, Denker M, Minn A, Shames DS, Sandler A, Chen DS, et al. Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A. Journal of Clinical Oncology. 33: 3015-3015. DOI: 10.1200/Jco.2015.33.15_Suppl.3015 |
0.505 |
|
| 2015 |
Gomez SL, Clarke CA, Yang J, Sandler A, Lin S. Abstract A28: Incidence trends of lung cancer among Chinese Americans in California, 1990-2010 Cancer Prevention Research. 8. DOI: 10.1158/1940-6215.Prev-14-A28 |
0.369 |
|
| 2015 |
Gomez SL, Clarke C, Yang J, Sandler A, Lin S. Abstract B38: Lung cancer survival among Chinese Americans in California, 2000-2010 Cancer Epidemiology, Biomarkers & Prevention. 24. DOI: 10.1158/1538-7755.Disp14-B38 |
0.443 |
|
| 2015 |
Mok TSK, Cappuzzo F, Jotte RM, Reck M, Papadimitrakopoulou V, Sandler A, Waterkamp D, Verret W, Shen Y, Socinski MA. 356TiPPhase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv528.13 |
0.48 |
|
| 2015 |
Herbst RS, Marinis Fd, Jassem J, Spigel DR, Shankar G, Mocci S, Sandler A, Lopez-Chavez A, Li S, Giaccone G. 355TiPPhase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naïve patients with advanced NSCLC Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv528.12 |
0.492 |
|
| 2015 |
Besse B, Johnson M, Janne PA, Garassino M, Eberhardt WEE, Peters S, Toh CK, Kurata T, Li Z, Kowanetz M, Mocci S, Sandler A, Rizvi NA. 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31938-4 |
0.556 |
|
| 2015 |
Schmid P, Kowanetz M, Koeppen H, Zou W, Wistuba I, Kockx M, Kadel E, Chaft J, Rizvi N, Hirsch F, Smith D, Miley N, Leveque V, Shames D, Sandler A, et al. 3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes European Journal of Cancer. 51: S602. DOI: 10.1016/S0959-8049(16)31661-6 |
0.543 |
|
| 2015 |
Vansteenkiste J, Fehrenbacher L, Spira A, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Yi J, He P, Kowanetz M, Waterkamp D, Ballinger M, Chen D, ... Sandler A, et al. 14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR) European Journal of Cancer. 51: S716-S717. DOI: 10.1016/S0959-8049(15)30072-1 |
0.607 |
|
| 2014 |
Soria JC, Gettinger S, Gordon M, Heist RS, Horn L, Spigel DR, Kowanetz M, Mokatrin A, Xiao Y, Sandler A, Felip E. 1322PBIOMARKERS ASSOCIATED WITH CLINICAL ACTIVITY OF PD-L1 BLOCKADE IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) IN A PHASE I STUDY OF MPDL3280A. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv465. PMID 28171533 DOI: 10.1093/Annonc/Mdu349.101 |
0.417 |
|
| 2014 |
Lammers PE, Shyr Y, Li CI, Hutchison AS, Sandler A, Carbone DP, Johnson DH, Keedy VL, Horn L. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 559-62. PMID 24736081 DOI: 10.1097/Jto.0000000000000079 |
0.427 |
|
| 2014 |
Rizvi NA, Chow LQM, Dirix LY, Gettinger SN, Gordon MS, Kabbinavar FF, Pawel JV, Soria J, Chappey C, Mokatrin A, Sandler A, Waterkamp D, Spigel DR. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps8123 |
0.456 |
|
| 2014 |
Pawel Jv, Scagliotti G, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Shepherd F, Spigel D, Hirsh V, Sequist L, Shuster D, Zahir H, ... ... Sandler A, et al. Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC) Pneumologie. 68. DOI: 10.1055/S-0034-1367776 |
0.491 |
|
| 2013 |
Crawford J, Swanson P, Schwarzenberger P, Sandler A, Prager D, Zhang K, Freeman DJ, Johnson CW, Krishnan K, Johnson D. A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 1510-8. PMID 24389433 DOI: 10.1097/Jto.0B013E3182A7D1Da |
0.468 |
|
| 2013 |
Gerber DE, Dahlberg SE, Sandler AB, Ahn DH, Schiller JH, Brahmer JR, Johnson DH. Baseline tumour measurements predict survival in advanced non-small cell lung cancer. British Journal of Cancer. 109: 1476-81. PMID 23942074 DOI: 10.1038/bjc.2013.472 |
0.398 |
|
| 2013 |
Robinson KW, Sandler AB. EGFR tyrosine kinase inhibitors: difference in efficacy and resistance. Current Oncology Reports. 15: 396-404. PMID 23674236 DOI: 10.1007/s11912-013-0323-7 |
0.305 |
|
| 2013 |
Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3068-77. PMID 23553849 DOI: 10.1158/1078-0432.Ccr-12-3381 |
0.496 |
|
| 2013 |
Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 20-30. PMID 23180113 DOI: 10.1093/annonc/mds590 |
0.453 |
|
| 2013 |
Horn L, Keedy VL, Campbell N, Garcia G, Hayes A, Spencer B, Carbone DP, Sandler A, Johnson DH. Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clinical Lung Cancer. 14: 14-8. PMID 22591607 DOI: 10.1016/J.Cllc.2012.03.008 |
0.453 |
|
| 2013 |
Duffy RM, Roesler G, Warrick A, Beadling C, Schuff K, Corless CL, Sandler A, Lopez-Chavez A. Tumor genotype and clinical outcomes for 229 patients with non-small cell lung cancer. Journal of Clinical Oncology. 31: e19141-e19141. DOI: 10.1200/Jco.2013.31.15_Suppl.E19141 |
0.443 |
|
| 2013 |
Langer CJ, Socinski MA, Patel JD, Sandler A, Schiller JH, Leon L, Uttamsingh S, Ramalingam SS. Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): Analyses based on age in the phase III PointBreak and E4599 trials. Journal of Clinical Oncology. 31: 8073-8073. DOI: 10.1200/Jco.2013.31.15_Suppl.8073 |
0.409 |
|
| 2013 |
Ahn DH, Dahlberg SE, Sandler A, Perry MC, Schiller JH, Brahmer JR, Johnson DH, Gerber DE. Association between baseline tumor dimensions and survival in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 31: 8046-8046. DOI: 10.1200/Jco.2013.31.15_Suppl.8046 |
0.481 |
|
| 2013 |
Sandler A, Taylor MH, Urba WJ, Omuro AMP, Anderson BD, Hansen D, Fisher B, Claeys AJ, Greathouse A, McLean S, Karmali RA. A phase I study of carboxyamidotriazole orotate (CTO) in of advanced solid tumors. Journal of Clinical Oncology. 31: 2518-2518. DOI: 10.1200/Jco.2013.31.15_Suppl.2518 |
0.352 |
|
| 2012 |
Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, Brahmer JR, Johnson DH, Sandler A. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1707-12. PMID 23059774 DOI: 10.1097/Jto.0B013E318265B500 |
0.479 |
|
| 2012 |
Sandler A, Hirsh V, Reck M, von Pawel J, Akerley W, Johnson DH. An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung Cancer (Amsterdam, Netherlands). 78: 1-7. PMID 22877947 DOI: 10.1016/J.Lungcan.2012.07.004 |
0.44 |
|
| 2012 |
Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1361-8. PMID 22843087 DOI: 10.1097/JTO.0b013e318260e106 |
0.39 |
|
| 2012 |
Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, von Pawel J, Schwartz B, Von Roemeling R, Sandler AB. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clinical Lung Cancer. 13: 391-5. PMID 22440336 DOI: 10.1016/j.cllc.2012.01.003 |
0.455 |
|
| 2012 |
Wakelee HA, Dahlberg SE, Brahmer JR, Schiller JH, Perry MC, Langer CJ, Sandler AB, Belani CP, Johnson DH. Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer (Amsterdam, Netherlands). 76: 410-5. PMID 22266041 DOI: 10.1016/j.lungcan.2011.12.006 |
0.326 |
|
| 2012 |
Lopez-Chavez A, Rajan A, Thomas A, Raffeld M, Xi L, Meltzer PS, Duffy RM, Pack S, Sandler A, Corless CL, Killian K, Oberholtzer C, Abdullaev Z, Giaccone G. Pilot trial of molecular profiling and targeted therapies in advanced thoracic malignancies: Non-small cell lung cancer, small cell lung cancer and thymic malignancies (CUSTOM). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps7609 |
0.457 |
|
| 2011 |
Sandler A, Schiller JH, Hirsh V, Sequist LV, Soria J, Von Pawel J, Wang Q, Pande AU, Schwartz BE, Garmey EG, Gorbatchevsky I, Scagliotti G. A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) . Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS217. PMID 28023476 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps217 |
0.501 |
|
| 2011 |
Bajorin DF, Sharma P, Sims RB, Sandler A, Lerner SP. Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS187. PMID 28023076 DOI: 10.1200/jco.2011.29.15_suppl.tps187 |
0.311 |
|
| 2011 |
Venepalli NK, Hutchison AS, Carbone DP, Johnson DH, Keedy VL, Pao W, Sandler A, Horn L. A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e17505. PMID 28020142 DOI: 10.1200/jco.2011.29.15_suppl.e17505 |
0.365 |
|
| 2011 |
Sandler A, Graham C, Baggstrom M, Herbst R, Zergebel C, Saito K, Jones D. An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1400-6. PMID 21673602 DOI: 10.1097/Jto.0B013E31820D7805 |
0.48 |
|
| 2011 |
Horn L, Zhao Z, Sandler A, Johnson D, Shyr Y, Wolff S, Devore RF, Laskin J. A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer. Clinical Lung Cancer. 12: 161-5. PMID 21663858 DOI: 10.1016/J.Cllc.2011.03.013 |
0.487 |
|
| 2011 |
Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, Sandler A, Johnson DH. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 103-8. PMID 21079521 DOI: 10.1097/Jto.0B013E3181Fa8Efd |
0.369 |
|
| 2011 |
Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, et al. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Medical Oncology (Northwood, London, England). 28: S152-61. PMID 20730572 DOI: 10.1007/s12032-010-9658-1 |
0.336 |
|
| 2011 |
Lovly CM, Li C, Hutchison AS, Carbone DP, Johnson DH, Keedy VL, Pao W, Sandler A, Horn L. A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC). Journal of Clinical Oncology. 29: 7094-7094. DOI: 10.1200/Jco.2012.30.15_Suppl.7094 |
0.455 |
|
| 2010 |
Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J, Schiller J, Johnson DH. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1416-23. PMID 20686429 DOI: 10.1097/Jto.0B013E3181Da36F4 |
0.477 |
|
| 2010 |
Robert F, Sandler A, Schiller JH, Liu G, Harper K, Verkh L, Huang X, Ilagan J, Tye L, Chao R, Traynor AM. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemotherapy and Pharmacology. 66: 669-80. PMID 20043166 DOI: 10.1007/S00280-009-1209-0 |
0.457 |
|
| 2010 |
Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer (Amsterdam, Netherlands). 69: 337-40. PMID 20036440 DOI: 10.1016/J.Lungcan.2009.11.019 |
0.501 |
|
| 2010 |
Blumenschein GR, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M, Sandler A. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 279-90. PMID 20028752 DOI: 10.1158/1078-0432.Ccr-09-1675 |
0.438 |
|
| 2010 |
Keedy VL, Lu B, Shyr Y, Horn L, Carbone DP, Sandler A, Johnson DH. A phase I study of nab-paclitaxel (nab-P) with carboplatin (C) and thoracic radiation (RT) in patients with locally advanced NSCLC. Journal of Clinical Oncology. 28: 7046-7046. DOI: 10.1200/Jco.2010.28.15_Suppl.E17504 |
0.405 |
|
| 2010 |
Johnson DH, Horn L, Zhao Z, Milne G, Morrow J, Sandler A, Shyr Y, Carbone DP. Eicosanoids in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 28: 7613-7613. DOI: 10.1200/Jco.2010.28.15_Suppl.7613 |
0.393 |
|
| 2010 |
Jones DV, Zergebel C, Saito K, Sandler A. A nonrandomized, multicenter, phase II study of S-1 with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 28: 7602-7602. DOI: 10.1200/Jco.2010.28.15_Suppl.7602 |
0.497 |
|
| 2009 |
Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8042. PMID 27962851 DOI: 10.1200/jco.2009.27.15_suppl.8042 |
0.315 |
|
| 2009 |
Zhang W, Dahlberg SE, Yang D, Sandler AB, Brahmer JR, Schiller JH, Carbone DP, Johnson DH, Lenz H. Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: Subset pharmacogenetic analysis of ECOG 4599. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8032. PMID 27962832 DOI: 10.1200/jco.2009.27.15_suppl.8032 |
0.302 |
|
| 2009 |
Horn L, Milne G, Sandler A, Morrow J, Carbone D, Shyr Y, Hayes A, Campbell N, Johnson DH. Urine PGE-M to assess prostaglandin E2 (PGE2) levels in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e19026. PMID 27962575 DOI: 10.1200/Jco.2009.27.15_Suppl.E19026 |
0.348 |
|
| 2009 |
Moretti L, Yu DS, Chen H, Carbone DP, Johnson DH, Keedy VL, Putnam JB, Sandler AB, Shyr Y, Lu B. Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. The Oncologist. 14: 1106-15. PMID 19897534 DOI: 10.1634/Theoncologist.2009-0130 |
0.349 |
|
| 2009 |
Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6006-11. PMID 19826110 DOI: 10.1200/JCO.2009.23.7545 |
0.42 |
|
| 2009 |
Horn L, Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer Clinical Cancer Research. 15: 5040-5048. PMID 19671872 DOI: 10.1158/1078-0432.CCR-09-0520 |
0.356 |
|
| 2009 |
Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, von Pawel J. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3836-41. PMID 19597027 DOI: 10.1200/JCO.2008.20.8355 |
0.423 |
|
| 2009 |
Jain AK, Hughes RS, Sandler AB, Dowlati A, Schwartzberg LS, Dobbs T, Schlabach L, Wu J, Muldowney NJ, Choy H. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 722-7. PMID 19404213 DOI: 10.1097/JTO.0b013e3181a5275c |
0.439 |
|
| 2009 |
Horn L, Sandler AB. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Clinical Lung Cancer. 10: S7-16. PMID 19362948 DOI: 10.3816/CLC.2009.s.002 |
0.427 |
|
| 2009 |
Horn L, Sandler AB. Angiogenesis in the treatment of non-small cell lung cancer. Proceedings of the American Thoracic Society. 6: 206-17. PMID 19349490 DOI: 10.1513/pats.200807-066LC |
0.404 |
|
| 2009 |
Herbst RS, Lynch TJ, Sandler AB. Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Clinical Lung Cancer. 10: 20-7. PMID 19289368 DOI: 10.3816/CLC.2009.n.003 |
0.42 |
|
| 2009 |
Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, Morrow JD, Sandler AB, Shyr Y, Ye F, Choy H. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2158-65. PMID 19276291 DOI: 10.1158/1078-0432.CCR-08-0629 |
0.421 |
|
| 2009 |
Horn L, Bernardo P, Sandler A, Wagner H, Levitan N, Levitt ML, Johnson DH. A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 527-33. PMID 19240650 DOI: 10.1097/JTO.0b013e31819c7daf |
0.425 |
|
| 2009 |
Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1405-12. PMID 19224857 DOI: 10.1200/JCO.2008.16.2412 |
0.356 |
|
| 2009 |
Kindler HL, Burris HA, Sandler AB, Oliff IA. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Investigational New Drugs. 27: 75-81. PMID 18618081 DOI: 10.1007/s10637-008-9160-1 |
0.323 |
|
| 2009 |
Cheng S, Dietrich M, Finnigan S, Sandler A, Crites J, Ferranti L, Wu A, Dilts D. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies Journal of Clinical Oncology. 27: CRA6509-CRA6509. DOI: 10.1200/Jco.2009.27.18_Suppl.Cra6509 |
0.399 |
|
| 2008 |
Sandler AB, Hirsh V, Reck M, Archer V, Samant MK, Wang L, Strickland DK, Dimery I, Johnson DH. Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8074. PMID 27948970 DOI: 10.1200/jco.2008.26.15_suppl.8074 |
0.301 |
|
| 2008 |
Archer V, Reck M, Sandler AB, Johnson DH, Kong G, Strickland DK, Bennouna J. Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8114. PMID 27948788 DOI: 10.1200/jco.2008.26.15_suppl.8114 |
0.389 |
|
| 2008 |
Dang TP, Salmon JS, Chen H, Chen S, Lee JW, Sandler AB, Herbst RS, Brahmer J, Carbone DP, Shyr Y. Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 11014. PMID 27948324 DOI: 10.1200/jco.2008.26.15_suppl.11014 |
0.361 |
|
| 2008 |
Hughes RS, Sandler AB, Jain AK, Dowlati A, Schwartzberg LS, Dobbs T, Schlabach L, Wu J, Muldowney NJ, Choy H. A phase II study of concurrent chemoradiotherapy with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7565. PMID 27947345 DOI: 10.1200/jco.2008.26.15_suppl.7565 |
0.428 |
|
| 2008 |
Herbst RS, Sandler A. Bevacizumab and erlotinib: A promising new approach to the treatment of advanced NSCLC Oncologist. 13: 1166-1176. PMID 18997180 DOI: 10.1634/Theoncologist.2008-0108 |
0.476 |
|
| 2008 |
Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5407-15. PMID 18936474 DOI: 10.1200/JCO.2008.17.3138 |
0.386 |
|
| 2008 |
O'Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, Hotko YS, Ganul VL, Kostinsky IY, Eisenfeld AJ, Sandalic L, Oldham FB, Bandstra B, Sandler AB, Singer JW. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 728-34. PMID 18594318 DOI: 10.1097/JTO.0b013e31817c6b68 |
0.415 |
|
| 2008 |
Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Investigational New Drugs. 26: 339-45. PMID 18463792 DOI: 10.1007/s10637-008-9133-4 |
0.305 |
|
| 2008 |
Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, Bonomi P. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2088-94. PMID 18381949 DOI: 10.1158/1078-0432.Ccr-07-4013 |
0.424 |
|
| 2008 |
Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1472-8. PMID 18349398 DOI: 10.1200/Jco.2007.13.0062 |
0.301 |
|
| 2008 |
Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1407-12. PMID 18316562 DOI: 10.1158/1078-0432.CCR-07-1154 |
0.322 |
|
| 2008 |
Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 60-5. PMID 18165641 DOI: 10.1200/JCO.2007.13.1144 |
0.434 |
|
| 2008 |
Pawel Jv, Larson T, Ou S, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski A, Schiller J. Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial Pneumologie. 62. DOI: 10.1055/S-2008-1074447 |
0.505 |
|
| 2007 |
Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4743-50. PMID 17909199 DOI: 10.1200/JCO.2007.12.3026 |
0.417 |
|
| 2007 |
Keedy VL, Sandler AB. Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Science. 98: 1825-30. PMID 17892508 DOI: 10.1111/j.1349-7006.2007.00620.x |
0.343 |
|
| 2007 |
Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, Morris D. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 132: 277S-289S. PMID 17873174 DOI: 10.1378/chest.07-1381 |
0.352 |
|
| 2007 |
Albert JM, Gonzalez A, Massion PP, Chen H, Olson SJ, Shyr Y, Diaz R, Lambright ES, Sandler A, Carbone DP, Putnam JB, Johnson DH, Lu B. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 1845-51. PMID 17855704 DOI: 10.1158/1055-9965.Epi-07-0146 |
0.342 |
|
| 2007 |
Sandler A. Bevacizumab in non-small cell lung cancer Clinical Cancer Research. 13. PMID 17671151 DOI: 10.1158/1078-0432.CCR-07-0647 |
0.418 |
|
| 2007 |
Horn L, Sandler A. Lung cancer adjuvant therapy Cancer Journal. 13: 210-216. PMID 17620772 DOI: 10.1097/PPO.0b013e318074d8f6 |
0.34 |
|
| 2007 |
Vansteenkiste J, Lara PN, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, Socinski MA, Delbaldo C, McHenry B, Lebwohl D, Peck R, Edelman MJ, Edelman M. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3448-55. PMID 17606973 DOI: 10.1200/JCO.2006.09.7097 |
0.457 |
|
| 2007 |
Horn L, Sandler AB, Putnam JB, Johnson DH. The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 2: 377-83. PMID 17473651 DOI: 10.1097/01.Jto.0000268669.64625.Bb |
0.405 |
|
| 2007 |
Horn L, Sandler A. Chemotherapy and antiangiogenic agents in non-small-cell lung cancer Clinical Lung Cancer. 8. PMID 17382027 DOI: 10.3816/CLC.2007.s.004 |
0.359 |
|
| 2007 |
Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M, White DA, Ratain MJ, Schiller JH, Sandler A, Kraut M, Mani S, Murren JR. Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1246-52. PMID 17317836 DOI: 10.1158/1078-0432.CCR-06-1096 |
0.34 |
|
| 2007 |
Ramies DA, Sandler A, Gray R, Giantonio B, Brahmer J, Lyons B, Schiller J. Bevacizumab: Analysis of clinical benefit in females across trials in colorectal cancer and non-small cell lung cancer Journal of Clinical Oncology. 25: 7634-7634. DOI: 10.1200/Jco.2007.25.18_Suppl.7634 |
0.441 |
|
| 2007 |
Sandler A, Szwaric S, Dowlati A, Moore DF, Schiller JH. A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): A trial of the Eastern Cooperative Oncology Group Journal of Clinical Oncology. 25: 7564-7564. DOI: 10.1200/Jco.2007.25.18_Suppl.7564 |
0.458 |
|
| 2007 |
Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler A, Schiller JH, Johnson DH. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study Journal of Clinical Oncology. 25: 7535-7535. DOI: 10.1200/Jco.2007.25.18_Suppl.7535 |
0.48 |
|
| 2007 |
Schiller JH, Larson T, Ou SI, Limentani SA, Sandler AB, Vokes EE, Kim S, Liau KF, Bycott PW, Olszanski AJ. Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial Journal of Clinical Oncology. 25: 7507-7507. DOI: 10.1200/JCO.2007.25.18_SUPPL.7507 |
0.349 |
|
| 2007 |
Robert F, Sandler A, Schiller JH, Ilagan J, VerMeulen W, Harper K, Liu G, Tye L, Chao R, Traynor A. A phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs) Journal of Clinical Oncology. 25: 3543-3543. DOI: 10.1200/Jco.2007.25.18_Suppl.3543 |
0.369 |
|
| 2007 |
Blumenschein GR, Sandler A, O’Rourke T, McGreivy J, Sun Y, Ye Y, Parson M, Stephenson JJ. PD3-3-7: Safety and Pharmacokinetics (PK) of AMG 706 With Carboplatin/Paclitaxel (C/P) and/or Panitumumab for the treatment of patients with advanced non-small cell lung cancer (NSCLC) Journal of Thoracic Oncology. 2: S469. DOI: 10.1097/01.JTO.0000283417.64982.90 |
0.423 |
|
| 2007 |
Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler A, Schiller JH, Johnson DH. PD3-3-5: Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): Analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study Journal of Thoracic Oncology. 2: S468. DOI: 10.1097/01.JTO.0000283415.19240.46 |
0.418 |
|
| 2007 |
Sandler A, Reck M, vonPawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Mezger J, Moore N, Manegold C. 6570 POSTER Results for progression-free survival (PFS) from two randomised, double-blind, multicentre phase III studies of bevacizumab in combination with platin-based chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) are comparable when analysed by similar populations and methodology European Journal of Cancer Supplements. 5: 379. DOI: 10.1016/S1359-6349(07)71398-8 |
0.464 |
|
| 2007 |
Traynor A, Sandler A, Schiller JH, Ilagan J, Harper K, VerMeulen W, Liu G, Tye L, Chao R, Robert F. 711 POSTER Sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors: a phase I dose-escalation and pharmacokinetic (PK) study Ejc Supplements. 5: 110. DOI: 10.1016/S1359-6349(07)70510-4 |
0.372 |
|
| 2007 |
Albert J, Gonzalez A, Diaz R, Massion P, Chen H, Shyr Y, Lambright E, Sandler A, Johnson D, Lu B. Cytoplasmic Clusterin Expression is Associated With Longer Survival in Patients With Resected Non-Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 69: S478-S479. DOI: 10.1016/J.IJROBP.2007.07.1677 |
0.37 |
|
| 2006 |
Langer CJ, Swann S, Werner-Wasik M, Lilenbaum R, Curran W, Sandler A, Scidmore N, Samuels M, Choy H. Phase I study of irinotecan (Ir) and cisplatin (DDP) in combination with thoracic radiotherapy (RT), either twice daily (45 Gy) or once daily (70 Gy), in patients with limited (Ltd) small cell lung carcinoma (SCLC): Early analysis of RTOG 0241. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 7058. PMID 27953171 DOI: 10.1200/Jco.2006.24.18_Suppl.7058 |
0.436 |
|
| 2006 |
Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, Johnson DH. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: 441-6. PMID 17409897 |
0.421 |
|
| 2006 |
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. The New England Journal of Medicine. 355: 2542-50. PMID 17167137 DOI: 10.1056/NEJMoa061884 |
0.303 |
|
| 2006 |
Vokes E, Herbst R, Sandler A. Angiogenesis inhibition in the treatment of lung cancer Clinical Advances in Hematology &Amp; Oncology : H&Amp;O. 4. PMID 17143257 |
0.403 |
|
| 2006 |
Govindan R, Crowley J, Schwartzberg L, Kennedy P, Williams C, Ekstrand B, Sandler A, Jaunakais D, Bolejack V, Ghalie R. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4848-54. PMID 17050870 DOI: 10.1200/JCO.2006.07.7404 |
0.458 |
|
| 2006 |
Sandler A, Herbst R. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4421s-4425s. PMID 16857821 DOI: 10.1158/1078-0432.CCR-06-0796 |
0.412 |
|
| 2006 |
Ramalingam S, Sandler AB. Salvage therapy for advanced non-small cell lung cancer: Factors influencing treatment selection Oncologist. 11: 655-665. PMID 16794244 DOI: 10.1634/theoncologist.11-6-655 |
0.438 |
|
| 2006 |
Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2038-43. PMID 16648503 DOI: 10.1200/JCO.2005.04.8595 |
0.457 |
|
| 2006 |
Laskin JJ, Sandler AB. First-line treatment for advanced non-small-cell lung cancer. Oncology (Williston Park, N.Y.). 19: 1671-6; discussion 1. PMID 16425521 |
0.436 |
|
| 2006 |
Herbst RS, Sandler AB. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? The Oncologist. 19-26. PMID 15178812 DOI: 10.1634/THEONCOLOGIST.9-SUPPL_1-19 |
0.445 |
|
| 2006 |
Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor V, Coon J, Buckingham L, Bonomi P. Gastrointestinal hemorrhage in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib and celecoxib Journal of Clinical Oncology. 24: 7172-7172. DOI: 10.1200/Jco.2006.24.18_Suppl.7172 |
0.497 |
|
| 2006 |
Blumenschein G, Sandler A, O’Rourke T, Eschenberg M, Sun Y, Gladish G, Salgia R, Alden C, Herbst RS, Reckamp K. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 24: 7119-7119. DOI: 10.1200/Jco.2006.24.18_Suppl.7119 |
0.409 |
|
| 2006 |
O’Brien M, Bonomi P, Langer C, O’Byrne K, Bandstra B, Ross H, Sandler A, Socinski M, Paz-Ares L. Analysis of prognostic factors in chemo-naïve patients with advanced NSCLC and poor performance status (PS): Cox regression analysis of two phase III trials Journal of Clinical Oncology. 24: 7113-7113. DOI: 10.1200/Jco.2006.24.18_Suppl.7113 |
0.472 |
|
| 2006 |
Govindan R, Crowley J, Schwartzberg L, Kennedy P, Williams C, Ekstrand B, Sandler A, Jaunakais D, Ghalie R. Final results of a phase II trial of bexarotene capsules as 3rd or subsequent line therapy in patients with advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 24: 7099-7099. DOI: 10.1200/JCO.2006.24.18_SUPPL.7099 |
0.416 |
|
| 2006 |
Fehrenbacher L, O'Neill V, Belani CP, Bonomi P, Hart L, Melnyk O, Sandler A, Ramies D, Herbst RS. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer Journal of Clinical Oncology. 24: 7062-7062. DOI: 10.1200/Jco.2006.24.18_Suppl.7062 |
0.529 |
|
| 2006 |
Bonomi P, Langer C, O'Brien M, O'Byrne K, Bandstra B, Paz-Ares L, Ross H, Sandler A, Socinski M. Analysis of prognostic factors in patients with advanced relapsed/refractory NSCLC: Cox regression analysis of a randomized phase III trial comparing docetaxel and paclitaxel poliglumex (PPX) Journal of Clinical Oncology. 24: 7040-7040. DOI: 10.1200/Jco.2006.24.18_Suppl.7040 |
0.497 |
|
| 2006 |
Ross H, Bonomi P, Langer C, O’Brien M, O’Byrne K, Paz-Ares L, Sandler A, Socinski M, Oldham F, Singer J. Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaive pts with advanced NSCLC and poor performance status (PS2) Journal of Clinical Oncology. 24: 7039-7039. DOI: 10.1200/Jco.2006.24.18_Suppl.7039 |
0.497 |
|
| 2006 |
Brahmer JR, Gray R, Schiller JH, Perry M, Sandler A, Johnson D. ECOG 4599 phase III trial of carboplatin and paclitaxel {+/-}bevacizumab: Subset analysis of survival by gender Journal of Clinical Oncology. 24: 7036-7036. DOI: 10.1200/Jco.2006.24.18_Suppl.7036 |
0.439 |
|
| 2006 |
Dowlati A, Gray R, Johnson DH, Schiller JH, Brahmer J, Sandler AB. Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 24: 7027-7027. DOI: 10.1200/JCO.2006.24.18_SUPPL.7027 |
0.318 |
|
| 2006 |
Miller VA, Zakowski M, Riely GJ, Pao W, Ladanyi M, Tsao AS, Sandler A, Herbst R, Kris MG, Johnson DH. EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial. Journal of Clinical Oncology. 24: 7003-7003. DOI: 10.1200/Jco.2006.24.18_Suppl.7003 |
0.408 |
|
| 2006 |
Kris MG, Giaccone G, Davies A, Fukuoka M, Garfield DH, Jassem J, Quoix EA, Sandler AB, Scagliotti GV, Meerbeeck JPV, West H. Systemic Therapy of Bronchioloalveolar Carcinoma: Results of the First IASLC/ASCO Consensus Conference on Bronchioloalveolar Carcinoma Journal of Thoracic Oncology. 1: 32. DOI: 10.1016/S1556-0864(15)30007-1 |
0.361 |
|
| 2005 |
Sandler AB, Gray R, Brahmer J, Dowlati A, Schiller JH, Perry MC, Johnson DH. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: LBA4. PMID 27946940 DOI: 10.1200/jco.2005.23.16_suppl.lba4 |
0.4 |
|
| 2005 |
Tsao AS, Herbst R, Sandler A, Seshagiri S, Wistuba I, Henderson T, Ramies D, Goddard A, Johnson D, Eberhard D. Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7092. PMID 27944559 DOI: 10.1200/Jco.2005.23.16_Suppl.7092 |
0.465 |
|
| 2005 |
Kris MG, Sandler A, Miller VA, Zakowski MF, Pao W, Tsao A, Patel JD, Johnson DH, Carbone DP. EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7029. PMID 27944467 DOI: 10.1200/Jco.2005.23.16_Suppl.7029 |
0.366 |
|
| 2005 |
Salmon JS, Sandler A, Billheimer D, Herbst RS, Tran HT, Tsao A, Dang TP. MALDI-TOF mass spectrometry proteomic profiling to discriminate response to the combination of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7022. PMID 27944463 DOI: 10.1200/Jco.2005.23.16_Suppl.7022 |
0.436 |
|
| 2005 |
Yee L, Lynch T, Villalona-Calero M, Rizvi N, Gabrail N, Sandler A, Cropp G, Palmer G. A phase II study of KOS-862 (epothilone D) as second-line therapy in non-small cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7127. PMID 27944229 DOI: 10.1200/jco.2005.23.16_suppl.7127 |
0.382 |
|
| 2005 |
Govindan R, Crowley J, Schwartzberg L, Kennedy P, Ekstrand BC, Sandler A, Jaunakais D, Ghalie R. Phase II trial of bexarotene capsules in patients with non-small-cell lung cancer (NSCLC) who have failed at least 2 prior systemic therapies for Stage IIIB/IV disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7116. PMID 27944207 DOI: 10.1200/jco.2005.23.16_suppl.7116 |
0.446 |
|
| 2005 |
Johnson BE, Ma P, West H, Kerr R, Prager D, Sandler A, Herbst RS, Stewart DJ, Dimery IW, Heymach JV. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1(st)-line treatment in patients with NSCLC. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7102. PMID 27944193 DOI: 10.1200/Jco.2005.23.16_Suppl.7102 |
0.479 |
|
| 2005 |
Hanna NH, Einhorn L, Sandler A, Langer C, Hariharan S, Ansari R, Ellis P, Byrne M, Wang B, Bunn P. Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: LBA7004. PMID 27943967 DOI: 10.1200/Jco.2005.23.16_Suppl.Lba7004 |
0.507 |
|
| 2005 |
Sandler AB. Targeting angiogenesis in lung cancer Seminars in Oncology. 32. PMID 16459175 DOI: 10.1053/J.SEMINONCOL.2005.10.006 |
0.325 |
|
| 2005 |
Laskin JJ, Sandler AB. State of the art in therapy for non-small cell lung cancer. Cancer Investigation. 23: 427-42. PMID 16193643 DOI: 10.1081/CNV-67172 |
0.384 |
|
| 2005 |
Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, Dang T, Carbone DP, Johnson DH. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6634-40. PMID 16166442 DOI: 10.1158/1078-0432.CCR-05-0436 |
0.361 |
|
| 2005 |
Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5892-9. PMID 16043829 DOI: 10.1200/Jco.2005.02.840 |
0.552 |
|
| 2005 |
Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, Ellerton J, Vokes EE, Green MR. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3752-9. PMID 15923572 DOI: 10.1200/JCO.2005.09.071 |
0.448 |
|
| 2005 |
Komaki R, Swann RS, Ettinger DS, Glisson BS, Sandler AB, Movsas B, Suh J, Byhardt RW. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. International Journal of Radiation Oncology, Biology, Physics. 62: 342-50. PMID 15890573 DOI: 10.1016/j.ijrobp.2004.11.030 |
0.326 |
|
| 2005 |
Herbst RS, Onn A, Sandler A. Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications Journal of Clinical Oncology. 23: 3243-3256. PMID 15886312 DOI: 10.1200/Jco.2005.18.853 |
0.39 |
|
| 2005 |
Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, ... ... Sandler A, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2544-55. PMID 15753462 DOI: 10.1200/Jco.2005.02.477 |
0.468 |
|
| 2005 |
Herbst RS, Sandler AB. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clinical Lung Cancer. S7-S19. PMID 15638959 DOI: 10.3816/CLC.2004.S.009 |
0.427 |
|
| 2005 |
Fuster LM, Sandler AB. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes. Clinical Lung Cancer. S24-9. PMID 15638954 DOI: 10.3816/CLC.2004.S.011 |
0.437 |
|
| 2005 |
Laskin JJ, Sandler AB, Johnson DH. Introduction: Non-Small Cell Lung Cancer Seminars in Oncology. 32: 251-252. DOI: 10.1053/J.SEMINONCOL.2005.04.014 |
0.321 |
|
| 2005 |
Laskin J, Shirley B, Dobbs T, Bi J, Carbone D, Johnson D, Sandler A. P-778 A phase II trial of carboplatin and irinotecan as first-line therapy for extensive stage small cell lung cancer (ES-SCLC): Preliminary results Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)81271-1 |
0.493 |
|
| 2005 |
Langer C, Swann S, Werner-Wasik M, Lillenbaum R, Curran W, Sandler A, Scidmore N, Choy H, Samuels M. P-777 Phase I study of combination irinotecan and cisplatin and either twice daily thoracic radiation (45Gy) or once daily thoracic radiotherapy (70Gy) in patients with limited small cell lung carcinoma (SCLC): Early toxicity analysis of RTOG 0241 Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)81270-X |
0.438 |
|
| 2005 |
Rizvi N, Villalona-Calero M, Lynch T, Yee L, Gabrail N, Sandler A, Cropp G, Graham M, Palmer G. P-565 A Phase II study of KOS-862 (Epothilone D) as second-linetherapy in non-small cell lung cancer Lung Cancer. 49: S266-S267. DOI: 10.1016/S0169-5002(05)81058-X |
0.344 |
|
| 2005 |
Hevmach J, West H, Kerr R, Prager D, Sandler A, Herbst R, Stewart D, Dimery I, Johnson B. P-497 ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized Phase II study Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)80990-0 |
0.446 |
|
| 2005 |
Freeman D, Juan T, Sarosi I, Crawford J, Sandler A, Schiller J, Prager D, Johnson D, Moss S, Radinsky R. PD-143 Analysis of EGFr gene mutations in non-small cell lungcarcinoma (NSCLC) patients (pts) treated with panitumumab plus paclitaxel and carboplatin or chemotherapy alone Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)80476-3 |
0.471 |
|
| 2005 |
Langer C, Hanna N, Einhorn L, Sandler A, Ansari R, Ellis P, Byrne M, Green M, Morrison M, Bunn P. O-156 Randomized, phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated, extensive-stage, small-cell lung cancer (SCLC) Lung Cancer. 49: S53-S54. DOI: 10.1016/S0169-5002(05)80290-9 |
0.516 |
|
| 2005 |
Sandler A, Kris M, Miller V, Carbone D, Pao W, Billheimer D, Tsao A, Patel J, Johnson B, Johnson D. O-109 Phase II trial of erlotinib in patients with bronchioloalveolarcarcinoma Lung Cancer. 49: S38-S39. DOI: 10.1016/S0169-5002(05)80243-0 |
0.369 |
|
| 2005 |
O'Brien M, Sandler A, Popovich A, Ganchev H, Bogdanova N, Miziara J. O-104 XYOTAXT™ vs. gemcitabine or vinorelbine for the treatment of performance status (PS) 2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The STELLAR 4 Phase III study Lung Cancer. 49: S37. DOI: 10.1016/S0169-5002(05)80238-7 |
0.439 |
|
| 2005 |
Sandler A, Gray R, Brahmer J, Dowlati A, Schiller J, Perry M, Johnson D. O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599 Lung Cancer. 49: S31. DOI: 10.1016/S0169-5002(05)80220-X |
0.407 |
|
| 2005 |
Wakelee H, Wang W, Schiller J, Langer C, Sandler A, Belani C, Johnson D. O-056 Survival differences by gender for patients with advancednon-small cell lung cancer in Eastern Cooperative Oncology Group trial 1594 Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)80188-6 |
0.46 |
|
| 2004 |
Herbst RS, Prager D, Hermann R, Miller V, Fehrenbacher L, Hoffman P, Johnson B, Sandler AB, Mass R, Johnson DH. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7011. PMID 28016269 DOI: 10.1200/Jco.2004.22.14_Suppl.7011 |
0.456 |
|
| 2004 |
Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Johnson D, Fleishman A, Lee S, Takeshita K. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7083. PMID 28016137 DOI: 10.1200/jco.2004.22.14_suppl.7083 |
0.389 |
|
| 2004 |
Miller VA, Herbst R, Prager D, Fehrenbacher L, Hermann R, Hoffman P, Johnson B, Sandler AB, Kris MG, Ramies D. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7061. PMID 28016112 DOI: 10.1200/Jco.2004.22.14_Suppl.7061 |
0.397 |
|
| 2004 |
Kris MG, Sandler A, Miller V, Cespon M, Zakowski M, Pizzo B, Venkatraman E, Gomez J, Johnson D, Carbone D. Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7062. PMID 28016100 DOI: 10.1200/Jco.2004.22.14_Suppl.7062 |
0.362 |
|
| 2004 |
Sandler AB, Blumenschein GR, Henderson T, Lee J, Truong M, Kim E, Mass B, Garcia B, Johnson DH, Herbst RS. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2000. PMID 28015797 DOI: 10.1200/Jco.2004.22.14_Suppl.2000 |
0.466 |
|
| 2004 |
Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4258s-4262s. PMID 15217970 DOI: 10.1158/1078-0432.CCR-040023 |
0.458 |
|
| 2004 |
Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, et al. Novel agents in the treatment of lung cancer: conference summary statement. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4199s-4204s. PMID 15217958 DOI: 10.1158/1078-0432.Ccr-040021 |
0.308 |
|
| 2004 |
Sandler AB, Dubinett SM. COX-2 inhibition and lung cancer. Seminars in Oncology. 31: 45-52. PMID 15179623 DOI: 10.1053/J.Seminoncol.2004.03.045 |
0.416 |
|
| 2004 |
Look KY, Sandler A, Blessing JA, Lucci JA, Rose PG. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study Gynecologic Oncology. 92: 644-647. PMID 14766260 DOI: 10.1016/J.Ygyno.2003.11.023 |
0.401 |
|
| 2004 |
Sandler A. Irinotecan: future directions in small-cell lung cancer. Clinical Lung Cancer. S9-S13. PMID 14725724 DOI: 10.3816/CLC.2001.S.002 |
0.433 |
|
| 2004 |
Csiki I, Williams MK, Shyr Y, Sandler A, Carbone DP, Campbell N, Morrow J, Johnson DH. Urine PGE-M as a marker of intratumoral cyclooxygenase-2 activity in non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 22: 9527-9527. DOI: 10.1200/Jco.2004.22.90140.9527 |
0.442 |
|
| 2004 |
Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Johnson D, Fleishman A, Lee S, Takeshita K. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 22: 7083-7083. DOI: 10.1200/JCO.2004.22.90140.7083 |
0.386 |
|
| 2003 |
Laskin JJ, Sandler AB. The role of prophylactic cranial radiation in the treatment of non-small-cell lung cancer Clinical Advances in Hematology &Amp; Oncology : H&Amp;O. 1: 731-734. PMID 16258477 |
0.353 |
|
| 2003 |
Sandler A. State-of-the-art treatment for advanced non-small-cell lung cancer Oncology (Williston Park, N.Y.). 17: 15-22. PMID 14723002 |
0.407 |
|
| 2003 |
Sandler A. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib Oncology (Williston Park, N.Y.). 17: 17-22. PMID 14682119 |
0.481 |
|
| 2003 |
Sandler AB. Molecular targeted agents in non-small-cell lung cancer Clinical Lung Cancer. 5. PMID 14641991 |
0.359 |
|
| 2003 |
Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama. 290: 2149-58. PMID 14570950 DOI: 10.1001/jama.290.16.2149 |
0.397 |
|
| 2003 |
Laskin J, Sandler A, Johnson DH. An advance in small-cell lung cancer treatment--more or less. Journal of the National Cancer Institute. 95: 1099-101. PMID 12902431 DOI: 10.1093/JNCI/DJG013 |
0.323 |
|
| 2003 |
Bunn PA, Shepherd FA, Sandler A, Chevalier TL, Belani CP, Kosmidis PA, Scagliotti GV, Giaccone G. Ongoing and future trials of biologic therapies in lung cancer Lung Cancer. 41: 175-186. PMID 12867076 DOI: 10.1016/S0169-5002(03)00161-2 |
0.46 |
|
| 2003 |
Laskin JJ, Sandler AB. The importance of the eicosanoid pathway in lung cancer. Lung Cancer (Amsterdam, Netherlands). S73-9. PMID 12867065 DOI: 10.1016/S0169-5002(03)00145-4 |
0.332 |
|
| 2003 |
Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, Krozely P, Sandler A, Carbone D, Heelan RT, Kris MG, Smith R, Ochs J. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2094-100. PMID 12775734 DOI: 10.1200/Jco.2003.12.008 |
0.504 |
|
| 2003 |
Masters GA, Declerck L, Blanke C, Sandler A, DeVore R, Miller K, Johnson DH. Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597 Journal of Clinical Oncology. 21: 1550-1555. PMID 12697880 DOI: 10.1200/Jco.2003.09.130 |
0.523 |
|
| 2003 |
Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Cancer Chemotherapy and Pharmacology. 51: 107-18. PMID 12647011 DOI: 10.1007/S00280-002-0542-3 |
0.31 |
|
| 2003 |
Sandler AB. Chemotherapy for small cell lung cancer Seminars in Oncology. 30: 9-25. PMID 12635086 DOI: 10.1053/sonc.2003.50012 |
0.377 |
|
| 2003 |
Herbst RS, Mininberg E, Henderson T, Kim E, Hong WK, Mass R, Novotny W, Garcia B, Johnson D, Sandler A. 977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer Ejc Supplements. 1. DOI: 10.1016/S1359-6349(03)91004-4 |
0.392 |
|
| 2003 |
Komaki R, Swann S, Ettinger D, Glisson B, Sandler A, Movsas B, Byhardt R. Phase I dose-escalation study of thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer (LSCLC). Radiation therapy oncology group RTOG International Journal of Radiation Oncology Biology Physics. 57. DOI: 10.1016/S0360-3016(03)00848-4 |
0.445 |
|
| 2003 |
Csiki I, Gonzalez A, Carbone DP, Gautam S, Sandler A, Campbell N, Garcia B, Morrow J, Johnson DH. P-357 Cyclooxygenase-2 (COX-2) inhibition in advanced non-small cell lung cancer (NSCLC): preliminary results of a phase II trial (THO-0054) Lung Cancer. 41: S182. DOI: 10.1016/S0169-5002(03)92325-7 |
0.422 |
|
| 2003 |
Choy H, Swann S, Sandler A, Whipple G, Demas WF, Ettinger D. P-171 A phase I trial of gemcitabine, carboplatin or gemcitabine, paclitaxel and concurrent radiation therapy followed by consolidative gemcitabine and carboplatin for inoperable stage III non-small cell lung cancer: An RTOG study Lung Cancer. 41: S133-S134. DOI: 10.1016/S0169-5002(03)92140-4 |
0.407 |
|
| 2003 |
Komaki R, Swann S, Ettinger D, Glisson B, Sandler A, Movsas B, Byhardt R. P-53 Phase I dose-escalation study of thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer (LSCLC). Radiation therapy oncology group (RTOG) protocol 9712 Lung Cancer. 41: S104. DOI: 10.1016/S0169-5002(03)92022-8 |
0.336 |
|
| 2003 |
Sandler A, Natale R, Blajman C, Kalemkerian G, Drinkard L, Fein L, Campbell A, Polli A, Vreeland F, Hirawat S. O-286 A phase II efficacy study of brostallicin, a novel minor groove binder (MGB), in patients (Pts) with platinum refractory or resistant non-small cell lung cancer (NSCLC) Lung Cancer. 41: S83. DOI: 10.1016/S0169-5002(03)91944-1 |
0.407 |
|
| 2003 |
Niell HB, Herndon J, Miller A, Watson D, Sandler A, Kelly K, Marks R, Perry M, Vokes E, Green M. O-277 CALGB 9732: Final report of a randomized phase III intergroup trial of etoposide(VP-16) and cisplatin (DDP) with or without paclitaxel(TAX) and G-CSF in patients with extensive stage small cell lung cancer(ED-SCLC) Lung Cancer. 41: S81. DOI: 10.1016/S0169-5002(03)91935-0 |
0.488 |
|
| 2003 |
Murren JR, White DD, Rizvi N, Kris M, Schiller J, Sandler A, Ryan C, Ratain M, Pass HI, Otterson G. O-142 Phase I and pharmacokinetic trial of inhalational doxorubicin (Resmycin™) Lung Cancer. 41. DOI: 10.1016/S0169-5002(03)91800-9 |
0.315 |
|
| 2003 |
Sandler AB, Mininberg E, Henderson T, Kim E, Hong WK, Mass R, Novotny W, Garcia B, Herbst R, Johnson D. O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer Lung Cancer. 41: S36. DOI: 10.1016/S0169-5002(03)91770-3 |
0.364 |
|
| 2003 |
Edelman MJ, Breton JL, Sandler A, Lara P, Bonomil P, LeChevalier T, Ardizzoni A, Paz-Ares L, Peck R, Vansteenkiste J. O-3 Randomized phase II study of the novel tubulin targetin agent, BMS-247550 (Epothilone B analogue) in the treatment of non-small cell lung cancer (NSCLC) in patients (pts) who have failed first line platinum containing therapy Lung Cancer. 41: S5. DOI: 10.1016/S0169-5002(03)91661-8 |
0.418 |
|
| 2002 |
Sandler A. Irinotecan in Small-Cell Lung Cancer: Current Data and the Status of Ongoing Trials Clinical Lung Cancer. 4. PMID 14659039 DOI: 10.3816/Clc.2002.S.020 |
0.492 |
|
| 2002 |
Sandler A. Irinotecan plus cisplatin in small-cell lung cancer Oncology (Williston Park, N.Y.). 16: 39-43. PMID 12375800 |
0.457 |
|
| 2002 |
Bhatia S, Hanna N, Ansari R, Einhorn L, Sandler A. Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC: A Hoosier Oncology Group (HOG) phase II study Lung Cancer. 38: 85-89. PMID 12367798 DOI: 10.1016/S0169-5002(02)00146-0 |
0.482 |
|
| 2002 |
Bhatia S, Hanna N, Ansari R, Pletcher W, Einhorn L, Ng E, Sandler A. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer. 38: 73-77. PMID 12367796 DOI: 10.1016/S0169-5002(02)00145-9 |
0.521 |
|
| 2002 |
Socinski MA, Sandler AB, Israel VK, Gillenwater HH, Miller LL, Locker PK, Antonellini A, Elfring GL, Natale RB. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma. Cancer. 95: 1520-7. PMID 12237921 DOI: 10.1002/cncr.10852 |
0.406 |
|
| 2002 |
Hinton S, Sandler A. Lung cancer in the elderly: Current and future chemotherapeutic options Drugs and Aging. 19: 365-375. PMID 12093323 DOI: 10.2165/00002512-200219050-00005 |
0.419 |
|
| 2002 |
Sandler A. Irinotecan therapy for small-cell lung cancer Oncology (Williston Park, N.Y.). 16: 419-425, 428, 433; d. PMID 12017533 |
0.424 |
|
| 2002 |
Hanna N, Ansari R, Fisher W, Shen J, Jung SH, Sandler A. Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study. Lung Cancer (Amsterdam, Netherlands). 35: 293-7. PMID 11844604 DOI: 10.1016/S0169-5002(01)00429-9 |
0.378 |
|
| 2002 |
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. 346: 92-8. PMID 11784875 DOI: 10.1056/Nejmoa011954 |
0.421 |
|
| 2001 |
Socinski MA, Sandler AB, Miller LL, Locker PK, Hanover CK, Elfring GL, Israel VK, Pirotta N, Natale RB. Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial. Clinical Lung Cancer. 2: S26-33. PMID 14725727 |
0.327 |
|
| 2001 |
Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma . Cancer. 92: 2639-47. PMID 11745199 DOI: 10.1002/1097-0142(20011115)92:10<2639::Aid-Cncr1617>3.0.Co;2-8 |
0.358 |
|
| 2001 |
Socinski MA, Sandler AB, Miller LL, Locker PK, Hanover CK, Elfring GL, Israel VK, Pirotta N, Natale RB. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 1078-87. PMID 11181672 DOI: 10.1200/JCO.2001.19.4.1078 |
0.459 |
|
| 2000 |
Sandler AB, Kindler HL, Einhorn LH, Mitchell E, Masters G, Kraut M, Nicol S, Raghavan D. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 11: 1161-4. PMID 11061612 DOI: 10.1023/A:1008369718242 |
0.392 |
|
| 2000 |
Sweeney CJ, Sandler AB. Chemotherapy in non-small cell lung cancer Investigational New Drugs. 18: 157-186. PMID 10857995 DOI: 10.1023/A:1006330030333 |
0.366 |
|
| 2000 |
Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 122-30. PMID 10623702 DOI: 10.1200/JCO.2000.18.1.122 |
0.494 |
|
| 1999 |
Sandler A, Van Oosterom AT. Irinotecan in cancers of the lung and cervix Anti-Cancer Drugs. 10. PMID 10630363 DOI: 10.1097/00001813-199911001-00003 |
0.445 |
|
| 1999 |
Ng EW, Sandler AB, Robinson L, Einhorn LH. A phase II study of carboplatin plus gemcitabine in advanced non-small- cell lung cancer (NSCLC): A hoosier oncology group study American Journal of Clinical Oncology: Cancer Clinical Trials. 22: 550-553. PMID 10597737 DOI: 10.1097/00000421-199912000-00003 |
0.446 |
|
| 1999 |
Sandler A, Ettinger DS. Gemcitabine: Single-Agent and Combination Therapy in Non-Small Cell Lung Cancer The Oncologist. 4: 241-251. DOI: 10.1634/THEONCOLOGIST.4-3-241 |
0.411 |
|
| 1998 |
Sandler A, Blanke C, Monaco F, Carey MA, Ansari R, Fisher B, Spiridonidis CH, Einhorn L, Nichols C. CODE (cisplatin, vincristine, doxorubicin, etoposide) plus granulocyte colony-stimulating factor in advanced non-small-cell lung cancer: A Hoosier oncology group phase II trial American Journal of Clinical Oncology: Cancer Clinical Trials. 21: 294-297. PMID 9626802 DOI: 10.1097/00000421-199806000-00019 |
0.477 |
|
| 1998 |
Sweeney CJ, Sandler AB. Treatment of advanced (stages III and IV) non-small-cell lung cancer. Current Problems in Cancer. 22: 85-132. PMID 9580849 DOI: 10.1016/S0147-0272(98)90010-1 |
0.404 |
|
| 1998 |
Mantravadi RVP, Sandler A, Montebello J, Ansari R, Nattam S, McClean J, Walker P, Einhorn L. A phase III hoosier oncology group study of thoracic radiotherapy (TRT) plus cisplatin (P) and vinblastin (V) with or without hydroxgurea (HX) for locally unresectable non small cell lung cancer (NSCLC) International Journal of Radiation Oncology Biology Physics. 42: 168. DOI: 10.1016/S0360-3016(98)80189-2 |
0.495 |
|
| 1998 |
Socinski M, Sandler A, Petit R, Steagall A, Hanover C, Natale R, Miller L. Phase III trial of paclitaxel (P), carboplatin (C), and irinotecan (CPT-11), in advanced or metastatic non-small-cell lung cancer (NSCLC) Lung Cancer. 21: S32-S33. DOI: 10.1016/S0169-5002(98)90062-9 |
0.437 |
|
| 1997 |
Sandler A, Raghavan D, Meropol N, Meyers T, Kindler H, Fox S, Perez R, Einhorn LH. A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors European Journal of Cancer. 33. DOI: 10.1016/S0959-8049(97)86030-3 |
0.411 |
|
| 1997 |
Abratt R, Sandler A, Crino L, Steward W, Shepherd F, Green M, Nguyen B. Dose scheduling & drug tolerability in phase II studies of gemcitabine and cisplstin chemotherapy for non-small cell lung cancer European Journal of Cancer. 33: S236-S237. DOI: 10.1016/S0959-8049(97)85869-8 |
0.369 |
|
| 1997 |
Sandler A, Ansari R, Fisher W, Gonin R, Levy R, Einhorn L. 266 A phase II study of VP-16 plus ifosfamide plus cisplatin (VIP) plus concurrent radiation therapy (XRT) for previously untreated limited small cell lung cancer (SCLC): A Hoosier Oncology Group (HOG) trial Lung Cancer. 18: 70. DOI: 10.1016/S0169-5002(97)89649-3 |
0.381 |
|
| 1997 |
Nguyen B, Sandler A, Crino L, Abratt R, Steward W, Green M. 31 Differential efficacy and toxicity profiles of 4 different schedules of gemcitabine and cisplatin combination in non-small cell lung cancer (NSCLC) Lung Cancer. 18: 11. DOI: 10.1016/S0169-5002(97)89310-5 |
0.387 |
|
| 1997 |
Sandler A. VP-16 plus ifosfamide plus cisplatin (VIP) in small cell lung cancer Lung Cancer. 18: 154. DOI: 10.1016/S0169-5002(97)83966-9 |
0.337 |
|
| 1996 |
Schultz MZ, Sandler AB, Durivage HJ, Cooper DL. A phase I pilot study of BCNU plus thymidine in patients with refractory cancer. Cancer Investigation. 14: 218-24. PMID 8630682 DOI: 10.3109/07357909609012142 |
0.306 |
|
| 1995 |
Faylona EA, Loehrer PJ, Ansari R, Sandler AB, Gonin R, Einhorn LH. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 13: 1209-14. PMID 7738623 DOI: 10.1200/JCO.1995.13.5.1209 |
0.419 |
|
| 1995 |
Loehrer PJ, Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, Einhorn LH. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. Journal of Clinical Oncology. 13: 2594-2599. PMID 7595712 DOI: 10.1200/Jco.1995.13.10.2594 |
0.424 |
|
| 1995 |
Sandler A, Ansari R, McClean J, Fisher W, Dorr F, Einhorn L. 1079 Gemcitabine plus cisplatin in non-small cell lung cancer: A phase II study European Journal of Cancer. 31: S225. DOI: 10.1016/0959-8049(95)96325-8 |
0.395 |
|
| 1992 |
Sandler AB, Buzaid AC. Lung cancer: A review of current therapeutic modalities Lung: An International Journal On Lungs, Airways and Breathing. 170: 249-265. PMID 1325579 DOI: 10.1007/BF00566678 |
0.401 |
|
| Show low-probability matches. |